ImmunoGen, Inc.
IMGNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for IMGN. That does not mean none is planned.
Get an email about IMGN's next catalysts
Track ImmunoGen (IMGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Single high dose of liposomal amphotericin B
Disseminated Histoplasma Capsulatum Infection
Pegylated Liposomal Doxorubicin
Epithelial Ovarian Cancer
Vacc-4x
HIV-1 Infection
Sterile water
HIV I Infection
IMGN853
Endometrial Cancer
SARS-CoV-2 DNA Vaccine (ICCOV)
COVID-19
Romidepsin
HIV I Infection
Vacc-C5/GM-CSF
HIV-1 Infection
Vacc-4x high dose
HIV Infection
Lorvotuzumab Mertansine (IMGN901)
Leukemia
GP2 peptide + GM-CSF vaccine
Breast Cancer
Vacc-4x low dose
HIV Infection
Vacc-C5/Alhydrogel
HIV-1 Infection
rhuGM-CSF
HIV-1 Infection
Vacc-4x medium dose
HIV Infection
AE37 + GM-CSF vaccine
Breast Cancer
IMGC936
Advanced Solid Tumor
BB-10901
Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Single high dose of liposomal amphotericin B | Phase 3 | Disseminated Histoplasma Capsulatum Infection | - | - |
Pegylated Liposomal Doxorubicin | Phase 3 | Epithelial Ovarian Cancer | - | - |
Vacc-4x | Phase 2 | HIV-1 Infection | - | - |
Sterile water | Phase 2 | HIV I Infection | - | - |
IMGN853 | Phase 2 | Endometrial Cancer | - | - |
SARS-CoV-2 DNA Vaccine (ICCOV) | Phase 2 | COVID-19 | - | - |
Romidepsin | Phase 2 | HIV I Infection | - | - |
Vacc-C5/GM-CSF | Phase 2 | HIV-1 Infection | - | - |
Vacc-4x high dose | Phase 2 | HIV Infection | - | - |
Lorvotuzumab Mertansine (IMGN901) | Phase 2 | Leukemia | - | - |
GP2 peptide + GM-CSF vaccine | Phase 2 | Breast Cancer | - | - |
Vacc-4x low dose | Phase 2 | HIV Infection | - | - |
Vacc-C5/Alhydrogel | Phase 2 | HIV-1 Infection | - | - |
rhuGM-CSF | Phase 2 | HIV-1 Infection | - | - |
Vacc-4x medium dose | Phase 2 | HIV Infection | - | - |
AE37 + GM-CSF vaccine | Phase 2 | Breast Cancer | - | - |
IMGC936 | Phase 2 | Advanced Solid Tumor | - | - |
BB-10901 | Phase 2 | Small Cell Lung Cancer | - | - |
Epithelial Ovarian Cancer
2 drugs in this indication
Small Cell Lung Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ImmunoGen, Inc.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in ImmunoGen, Inc.'s (IMGN) pipeline across Phase 3, Phase 2. Its lead program is Mirvetuximab Soravtansine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ImmunoGen, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ImmunoGen, Inc. (IMGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMGN biotech catalysts?→
Add IMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ImmunoGen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.